Virtu KCG Holdings LLC reduced its position in Agenus Inc. (NASDAQ:AGEN) by 66.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,654 shares of the biotechnology company’s stock after selling 49,799 shares during the quarter. Virtu KCG Holdings LLC’s holdings in Agenus were worth $100,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AGEN. Bank of New York Mellon Corp raised its position in shares of Agenus by 38.1% in the 1st quarter. Bank of New York Mellon Corp now owns 560,799 shares of the biotechnology company’s stock worth $2,114,000 after buying an additional 154,715 shares during the period. UBS Asset Management Americas Inc. raised its position in shares of Agenus by 203.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock worth $196,000 after buying an additional 34,833 shares during the period. SG Americas Securities LLC raised its position in shares of Agenus by 175.7% in the 1st quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock worth $140,000 after buying an additional 23,689 shares during the period. American International Group Inc. raised its position in shares of Agenus by 7.1% in the 1st quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,984 shares during the period. Finally, Vanguard Group Inc. raised its position in Agenus by 6.8% in the first quarter. Vanguard Group Inc. now owns 3,356,423 shares of the biotechnology company’s stock valued at $12,653,000 after purchasing an additional 215,151 shares during the period. 39.55% of the stock is currently owned by institutional investors and hedge funds.

In other Agenus news, CEO Garo H. Armen acquired 100,000 shares of Agenus stock in a transaction that occurred on Monday, October 30th. The stock was acquired at an average price of $3.55 per share, with a total value of $355,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.60% of the stock is currently owned by insiders.

AGEN has been the topic of several research reports. ValuEngine lowered Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research report on Wednesday, October 25th. BidaskClub raised Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Agenus in a research report on Friday, August 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $5.81.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $6.66 million. During the same period in the previous year, the firm posted ($0.33) EPS. The firm’s revenue for the quarter was down 36.1% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: “Virtu KCG Holdings LLC Cuts Position in Agenus Inc. (AGEN)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/virtu-kcg-holdings-llc-cuts-position-in-agenus-inc-agen/1674975.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.